Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population
Tóm tắt
Congenital afibrinogenemia (OMIM #202400) is a rare coagulation disorder that was first described in 1920. It is transmitted as an autosomal recessive trait that is characterized by absent levels of fibrinogen (factor I) in plasma. Consanguinity in Pakistan and its neighboring countries has resulted in a higher number of cases of congenital fibrinogen deficiency in their respective populations. This study focused on the detection of mutations in fibrinogen genes using DNA sequencing and molecular modeling of missense mutations in all three genes [Fibrinogen gene alpha (FGA), beta (FGB) and gamma (FGG)] in Pakistani patients. This descriptive and cross sectional study was conducted in Karachi and Lahore and fully complied with the Declaration of Helsinki. Patients with fibrinogen deficiency were screened for mutations in the Fibrinogen alpha (FGA), beta (FGB) and gamma (FGG) genes by direct sequencing. Molecular modeling was performed to predict the putative structure functional impact of the missense mutations identified in this study. Ten patients had mutations in FGA followed by three mutations in FGB and three mutations in FGG, respectively. Twelve of these mutations were novel. The missense mutations were predicted to result in a loss of stability because they break ordered regions and cause clashes in the hydrophobic core of the protein. Congenital afibrinogenemia is a rapidly growing problem in regions where consanguinity is frequently practiced. This study illustrates that mutations in FGA are relatively more common in Pakistani patients and molecular modeling of the missense mutations has shown damaging protein structures which has profounding effect on phenotypic bleeding manifestations in these patients.
Tài liệu tham khảo
Peyvandi F, Haertel S, Knaub S, Mannucci P. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. Journal of Thrombosis and Haemostasis. 2006;4:1634–7.
Acharya S, Dimichele D. Rare inherited disorders of fibrinogen. Haemophilia. 2008;14:1151–8.
Neerman-Arbez M, De Moerloose P, Bridel C, Honsberger A, Sconborner A, Rossier C, Peerlinck K, Claeyssens S, Di Michele D, D'oiron R, Dreyfus M, Laubriat-Bianchin M, Dieval J, Antonarakis SE, Morris MA. Mutations in the fibrinogen Aa gene account for the majority of cases of congenital afibrinogenemia. Blood. 2000;96:149–52.
Janciauskiene S, Welte T, Mahadev R. Acute Phase Proteins: Structure and Function Relationship. Acute Phase Proteins - Regulation and Functions of Acute Phase Proteins. 2011;.
Neerman-Arbez M, De Moerloose P, Honsberger A, Parlier G, Arnuti B, Biron C, Borg J, Eber S, Meili E, Peter-Salonen K, Ripoll L, Vervel C, d'Oiron R, Staeger P, Antonarakis SE, Morris MA. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes. Human genetics. 2001;108:237–40.
Anwar M, Iqbal H, Gul M, Saeed N, Ayyub M. Congenital afibrinogenemia: report of three cases. Journal of Thrombosis and Haemostasis. 2005;3:407–9.
Neerman-Arbez M, De Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Human Mutation. 2007;28:540–53.
Asselta R, Duga S, Tenchini M. The molecular basis of quantitative fibrinogen disorders. Journal of Thrombosis and Haemostasis. 2006;4:2115–29.
Grieninger G, Lu X, Cao Y, Fu Y, Kudryk BJ, Galanakis DK, Hertzberg KM. Fib420, the novel fibrinogen subclass: newborn levels are higher than adult. Blood. 1997;90:2609–14.
Fang Y, DAI B, WANG X, FU Q, Dai J, Xie F, CAI X, WANG H, WANG Z. Identification of three FGA mutations in two Chinese families with congenital afibrinogenaemia. Haemophilia. 2006;12:615–20.
Asselta R, Duga S, Simonic T, Malcovati M, Santagostino E, Giangr EP, Mannucci P, Tenchini M. Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation. Blood. 2000;96:2496–500.
Casini A, Neerman-Arbez M, Ariëns R, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. Journal of Thrombosis and Haemostasis. 2015;13(6):909–19.
Asselta R, Spena S, Duga S, Peyv IF, Malcovati M, Mannucci P, Tenchini M. Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. Haematologica. 2002;87:855–9.
Wu S, Wang Z, Dong N, Bai X, Ruan C. A novel nonsense mutation in the FGA gene in a Chinese family with congenital afibrinogenaemia. Blood coagulation & fibrinolysis. 2005;16(3):221–6.
Sumitha E, Jayandharan G, Arora N, Abraham A, David S, Devi GS, Shenbagapriya P, Nair SC, George B, Mathews V, Chandy M, Viswabandya A, Srivastava A. Molecular basis of quantitative fibrinogen disorders in 27 patients from India. Haemophilia. 2013;19:611–8.
Tyrrell DAJ. Polymerase Chain Reaction. BMJ. 1997;314(7073):5–5.
Sanger Sequencing Method | Thermo Fisher Scientific [Internet]. Thermofisher.com. 2017 [cited 2 Febuary 2017]. Available from: https://www.thermofisher.com/pk/en/home/lifescience/sequencing/sanger-sequencing/sanger_sequencing_method.html
Korte W, Poon M, Iorio A, Makris M. Thrombosis in Inherited Fibrinogen Disorders. Transfusion Medicine and Hemotherapy. 2017;44(2):70–6.
Neerman-Arbez M. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. Blood. 2003;101(9):3492–4.
VU D, NEERMAN-ARBEZ M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. Journal of Thrombosis and Haemostasis. 2007;5:125–31.
Robert-Ebadi H, De Moerloose P, El Khorassani M, El Khattab M, Neerman-Arbez M. A novel frameshift mutation in FGA accounting for congenital afibrinogenemia predicted to encode an aberrant peptide terminating 158 amino acids downstream. Blood Coagulation & Fibrinolysis. 2009;20(5):385–7.
Levrat E, Aboukhamis I, de Moerloose P, Farho J, Chamaa S, Reber G, et al. A novel frameshift mutation in FGA (c.1846 del A) leading to congenital afibrinogenemia in a consanguineous Syrian family. Blood Coagulation & Fibrinolysis. 2011;22(2):148–50.
Asselta R, Platè M, Robusto M, Borhany M, Guella I, Soldà G, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thrombosis and Haemostasis. 2014;113(3):567–76.
Palermo P, Barbados B, Asselta R, Duga S, Tenchini M. The molecular basis of quantitative fibrinogen disorders. Journal of Thrombosis and Haemostasis. 2006;4:2115–29.
Sheen C, Brennan S, Jabado N, George P. Fibrinogen Montreal: a novel missense mutation (A alpha D496N) associated with hypofibrinogenemia. Thrombosis and haemostasis. 2006;96:231–2.
Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici A, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766–73.